庫欣氏疾病 (Cushing’s disease, CD) 是由於促腎上腺皮質腫瘤過度分泌促腎上腺皮質激素 (adrenocorticotrophic hormone, ACTH) 所導致皮質醇 (cortisol) 過量而產生的疾病。Pasireotide 是第一個直接作用於腦下垂體腫瘤，直接抑制ACTH 分泌的藥物，用來治療庫欣氏疾病(CD)，於2012 年12 月經FDA 核准上市。Pasireotide 皮下注射給藥一天兩次，可有效地降低尿液中皮質醇的濃度，並且可以降低體重、血壓及血脂，改善病人的生活品質，建議用於無法進行手術、手術治療失敗或等待放射治療產生效果的病人身上。
 

Cushing’s disease is an excessive cortisol production stimulated by adrenocorticotrophic hormone (ACTH) from the pituitary adenoma. Pasireotide was the first drug approved by FDA in December 2012 for use in Cushing’s disease by direct inhibiting the secretion of ACTH from the pituitary adenoma. Twice-daily pasireotide subcutaneous injection can effectively decrease urine cortisol concentration, body weight, blood pressure and cholesterol, demonstrating its ability to improve quality of life in patients. Pasireotide injection is suggested to treat Cushing's disease in patients those who failed, cannot have surgery, or awaiting the effects of radiotherapy.